Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
Brain atrophy
Cortical lesions
Multiple sclerosis
Neurodegeneration
Ocrelizumab
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
23
10
2023
accepted:
27
12
2023
revised:
26
12
2023
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
30
1
2024
Statut:
aheadofprint
Résumé
Ocrelizumab (OCR) and Fingolimod (FGL) are two high-efficacy treatments in multiple sclerosis which, besides their strong anti-inflammatory activity, may limit neurodegeneration. To compare the effect of OCR and FGL on clinical and MRI endpoints. 95 relapsing-remitting patients (57 OCR, 38 FGL) clinically followed for 36 months underwent a 3-Tesla MRI at baseline and after 24 months. The annualized relapse rate, EDSS, new cortical/white matter lesions and regional cortical and deep grey matter volume loss were evaluated. OCR reduced the relapse rate from 0.48 to 0.04, FGL from 0.32 to 0.05 (both p < 0.001). Compared to FGL, OCR-group experienced fewer new white matter lesions (12% vs 32%, p = 0.005), no differences in new cortical lesions, lower deep grey matter volume loss (- 0.12% vs - 0.66%; p = 0.002, Cohen's d = 0.54), lower global cortical thickness change (- 0.45% vs - 0.70%; p = 0.036; d = 0.42) and reduced cortical thinning/volume loss in several regions of interests, including those of parietal gyrus (d-range = 0.65-0.71), frontal gyrus (d-range = 0.47-0.60), cingulate (d-range = 0.41-0.72), insula (d = 0.36), cerebellum (cortex d = 0.72, white matter d = 0.44), putamen (d = 0.35) and thalamus (d = 0.31). The effect on some regional thickness changes was confirmed in patients without focal lesions. When compared with FGL, patients receiving OCR showed greater suppression of focal MRI lesions accumulation and lower cortical and deep grey matter volume loss.
Identifiants
pubmed: 38289534
doi: 10.1007/s00415-023-12179-y
pii: 10.1007/s00415-023-12179-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Faissner S, Plemel JR, Gold R, Yong VW (2019) Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, vol 18
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132–1140
doi: 10.1001/jamaneurol.2020.1568
pubmed: 32511687
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234
doi: 10.1056/NEJMoa1601277
pubmed: 28002679
Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75(1):43–49
doi: 10.1002/ana.24018
pubmed: 24006277
Arnold DL, Sprenger T, Bar-or A, Wolinsky JS, Kappos L, Kolind S et al (2022) Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS, pp 1–10
Kolind S, Gaetano L, Assemlal HE, Bernasconi C, Bonati U, Elliott C, Hagenbuch N, Magon S, Arnold DL, Traboulsee A (2023) Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. Mult Scler 29(6):741–747
doi: 10.1177/13524585231162586
pubmed: 37148240
pmcid: 10176619
Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S et al (2017) A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci 383:221–229
doi: 10.1016/j.jns.2017.10.019
pubmed: 29146095
Bajrami A, Pitteri M, Castellaro M, Pizzini F, Romualdi C, Montemezzi S et al (2018) The effect of fingolimod on focal and diffuse grey matter damage in active MS patients. J Neurol 265(9):2154–2161
doi: 10.1007/s00415-018-8952-2
pubmed: 29938336
Pitteri M, Magliozzi R, Bajrami A, Camera V, Calabrese M (2018) Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables, vol 19, Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd, pp 387–95
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263–1273
doi: 10.1016/S0140-6736(18)30475-6
pubmed: 29576505
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), pp 1444–53
Havrdova E, Galetta S, Stefoski D, Comi G (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Issue 7 Suppl 3):S3-7
pubmed: 20421571
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4(4):329–333
doi: 10.1016/j.msard.2015.04.006
pubmed: 26195051
Geurts JJG, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT et al (2011) Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 76(5):418–424
doi: 10.1212/WNL.0b013e31820a0cc4
pubmed: 21209373
Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138(Pt 7):1863–1874
doi: 10.1093/brain/awv105
pubmed: 25902415
Schmidt P, Gaser C, Arsic M, Buck D, Förschler A, Berthele A et al (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 59(4):3774–3783
doi: 10.1016/j.neuroimage.2011.11.032
pubmed: 22119648
Valverde S, Oliver A, Lladó X (2014) A white matter lesion-filling approach to improve brain tissue volume measurements. NeuroImage Clin 6:86–92
doi: 10.1016/j.nicl.2014.08.016
pubmed: 25379419
pmcid: 4215527
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401
doi: 10.1056/NEJMoa0909494
pubmed: 20089952
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950–958. https://doi.org/10.1002/ana.24651
doi: 10.1002/ana.24651
pubmed: 27038238
Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J (2022) Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. J Neurol 269(6):3295–3300
doi: 10.1007/s00415-021-10950-7
pubmed: 34982200
pmcid: 8725429
Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, Bruschi N, Minguzzi S, Ivaldi F, Poirè I, Laroni A, Mancardi G, Capello E, Uccelli A, Novi G, Inglese M (2021) Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics 18(4):2579–2588
doi: 10.1007/s13311-021-01104-8
pubmed: 34553320
pmcid: 8457546
Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62(7):723–732
doi: 10.1093/jnen/62.7.723
pubmed: 12901699
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early disease onset and severe cortical pathology. Brain 130(Pt 4):1089–1104
pubmed: 17438020
Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL (2019) Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 142(9):2787–2799
doi: 10.1093/brain/awz212
pubmed: 31497864
pmcid: 6736181
Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, Rossi S, Pitteri M, Benedetti MD, Gajofatto A, Pizzini FB, Montemezzi S, Rasia S, Capra R, Bertoldo A, Facchiano F, Monaco S, Reynolds R, Calabrese M (2018) Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83(4):739–755
doi: 10.1002/ana.25197
pubmed: 29518260
Magliozzi R, Scalfari A, Pisani AI, Ziccardi S, Marastoni D, Pizzini FB, Bajrami A, Tamanti A, Guandalini M, Bonomi S, Rossi S, Mazziotti V, Castellaro M, Montemezzi S, Rasia S, Capra R, Pitteri M, Romualdi C, Reynolds R, Calabrese M (2020) The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol 88(3):562–573
doi: 10.1002/ana.25786
pubmed: 32418239
Bajrami A, Magliozzi R, Pisani AI, Pizzini FB, Crescenzo F, Marastoni D, Calabrese M (2022) Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. Mult Scler 28(4):550–560
doi: 10.1177/13524585211031786
pubmed: 34378437
Calabrese M, Rinaldi F, Grossi P, Gallo P (2011) Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother 11(3):425–432
doi: 10.1586/ern.10.155
pubmed: 21375447
Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J, Zheng H et al (eds) (2018) Impact of ocrelizumab on cognition in patients at increased risk of progressive disease (P1.420). AAN
Cohan S, Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J et al (eds) (2018) Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials (S44.005). AAN. https://n.neurology.org/content/90/15_Supplement/ S44.005 Platform Presentation S44.005. Accessed 8 Nov 2021
Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S et al (2021) Recovery of cognitive function after relapse in multiple sclerosis. Mult Scler 27(1):71–78
doi: 10.1177/1352458519898108
pubmed: 31971066